What is the association of preoperative biopsy with recurrence and survival in retroperitoneal sarcoma? A systematic review by the Australia and New Zealand Sarcoma Association clinical practice guidelines working party.

Preoperative biopsy for retroperitoneal sarcoma (RPS) enables appropriate multidisciplinary treatment planning. A systematic review of literature from 1990 to June 2022 was conducted using the population, intervention, comparison and outcome model to evaluate the local recurrence and overall survival of preoperative biopsy compared to those that had not. Of 3192 studies screened, five retrospective cohort studies were identified. Three reported on biopsy needle tract seeding, with only one study reporting biopsy site recurrence of 2 %. Two found no significant difference in local recurrence and one found higher 5-year local recurrence rates in those who had not been biopsied. Three studies reported overall survival, including one with propensity matching, did not show a difference in overall survival. In conclusion, preoperative core needle biopsy of RPS is not associated with increased local recurrence or adverse survival outcomes.
Competing Interests: Declaration of Competing Interest Stephanie Webster: Nil. Ana Cristina Vargas: Nil. Fiona Maclean: Nil. Jennifer Vu: Nil. Elissa Tong: Nil. David Coker: Nil. Iain Ward: Nil. Elizabeth Connolly: Nil. Deborah Di-Xin Zhou: Nil. Jasmine Mar: Nil. Smaro Lazarakis: Nil. David E Gyorki: Honorarium from BMS and Merck. Angela M Hong: Honorarium from Oncobeta and Telix.
(Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)